Hepatitis as a travelers' disease;Hepatitis als reisekrankheit

Internist

Volumn 45, Issue 6, 2004, Pages 655-668

  Hadem, J ^a   Wedemeyer, H ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hepatitis; Hepatitis viruses; Infection; Travel medicine; Vaccination

Indexed keywords

ADEFOVIR; ERWACHSENE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOGLOBULIN; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE;

ARTICLE; ASIA; CLINICAL FEATURE; DELTA AGENT HEPATITIS; DEVELOPED COUNTRY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; INDIA; INFECTION RISK; LABORATORY TEST; PREVALENCE; RISK FACTOR; SAFE SEX; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; TRAVEL; VACCINATION; VIRUS HEPATITIS; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; HEPATITIS, VIRAL, HUMAN; HUMANS; RISK ASSESSMENT; RISK FACTORS; TRAVEL; VIRAL HEPATITIS VACCINES;

EID: 3042745703     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-004-1197-4     Document Type: Article

References (57)

1. - (2003) Branchenbild Nr. 3. Gruner & Jahr, Hamburg
2. Craig AS, Schaffner W (2004) Prevention of hepatitis A with hepatitis A vaccine. N Engl J Med 350: 476-481
3. Koff RS (1995) Seroepidemiology of hepatitis A in the United States. J Infect Dis 171: S19-23
4. Lemon SM (2000) Hepatitis A virus. Update on viral hepatitis. American Association for the Study of Liver Diseases, p 48
5. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW (1985) Frequency of illness associated with epidemic hepatitis A virus infections in adults. A J Epidemiol 122: 226-233
6. Steffen R (1995) Hepatitis A in travelers: The European experience. J Infect Dis 171: S24-28
7. Manns MP, Scholer A (1999) Reisen und Hepatitis. Internist 40: 1137-1142
8. Gillies P, Slack R, Stoddart N, Convay S (1992) HIV-related risk behaviour in UK holiday-makers. AIDS 5: 339-441
9. Hawkes S, Hart GJ, Johnson AM et al. (1994) Risk behaviour and HIV prevalence in interregional travelers. AIDS 8: 247-252
10. Moore J, Beeker C, Harrison JS, Eng TR, Doll LS (1995) HIV risk behaviour among Peace Corps volunteers. AIDS 9: 795
11. Zwar NA (2003) Hepatitis risk and vaccination among Australian travellers overseas. M J Aust 178: 469-70
12. Herck KV, Damme PV, Castelli F et al. (2004) Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med 11: 3-7
13. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, Type A. National Centers for Infectious Diseases-http://www.travellers-health.com
14. Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E (1994) Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol Infect 113: 113-120
15. Webster G, Barnes E, Dusheiko G (2001) Protecting travelers from hepatitis A. Vaccine shoueld be used for almost every occasion when prevention is required. BMJ 322: 1194-1195
16. Ciccozzi M, Tosti ME, Gallo G et al. (2002) Risk of hepatitis A infection following travel. J Viral Hepatitis 9: 460-465
17. Steffen R (1991) Travel medicine 2. In: Lobel HO, Steffen R, Kozarsky PE (eds) Proceedings of the second conference on international travel medicine. Atlanta, USA
18. Bell BP, Shapiro CN, Alter MJ et al. (1998) The diverse patterns of hepatitis A epidemiology in the United States - implication for vaccination strategies. J Infect Dis 178: 1579-1584
19. Hadem J (2003) Immunopathogenesis and treatment of hepatitis A. In: Gershwin ME, Vierling JM, Manns MP (eds) Liver immunology. Hanley & Belfus, Philadelphia, pp 185-201
20. - (2000) Hepatitis A - Erkennung und Verhütung: Merkblatt für Ärzte. Bundesgesundheitsblatt 43: 257-259
21. Feinstone SM, Kapikian AZ, Purcell RH (1973) Hepatitis A: Detection by immune electron microscopy of a virus like antigen associated with acute illness. Science 182: 1026-1028
22. Innis BL, Snitbhan R, Kunasol P et al. (1994) Protection against hepatitis A by an inactivated vaccine. JAMA 271: 1328-1334
23. Werzberger A, Mensch B, Kuter B et al. (1992) A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327: 453-457
24. Lee SD, Chan CY, Yu MI et al. (1997) Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 52: 215-218
25. Keeffe EB, Iwarson S, McMahon BJ et al. (1998) Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27: 881-886
26. Arslan M, Wiesner RH, Poterucha JJ, Zein NN (2001) Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 72: 272-276
27. Wolters B, Junge U, Dziuba S, Roggendorf M (2003) Immunogenicity of combinded hepatitis A and B vaccine in elderly persons. Vaccine 21: 3623-3628
28. STIKO (2000) Mitteilungen der Ständigen Impfkommission (STIKO) zur Hepatitis-A- und -B-Impfung. Epidemiol Bull 10: 81
29. Fishbain JT, Eckart RE, Harner KC, Hospenthal DR (2002) Empiric immunization versus serologic screening: developing a cost-effective strategy für the use of hepatitis A immunization in travelers. J Travel Med 9: 71-75
30. Hadem J, Wedemeyer H, Scholz H, Manns MP (2004) Chronische Hepatitis. In: Adam D, Doerr HW, Link H, Lode H (Hrsg) Die Infektiologie. Springer, Berlin Heidelberg New York Tokio, S S13-S33
31. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, type B. National Centers for Infectious Diseases-http.//www.travellers-health.com
32. Guidotti LG, Chisari FV (2000) Cytokine-mediated control of viral infections. Virology 273: 221-227
33. Manns MP, Hadem J, Wedemeyer H (2004) Hepatitis B virus: where are we and where are we going? Methods Mol Med 96: 415-444
34. Hadem J, Wiegand J, Manns MP (2002) Chronische Hepatitiden - wann und wie therapieren? Hausarzt 20: 54-60
35. STIKO (2003) Empfehlungen der ständigen Impfkommission (STIKO) am Robert-Koch-Institut. Epidemiol Bull 32
36. Margolis H (2000) Hepatitis B vaccine. In: American Association for the Study of Liver Diseases (ed) Update on viral hepatitis. Dallas, pp 88-91
37. Wolters B, Junge U, Dziuba S, Roggendorf M (2003) Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21: 3623-3628
38. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC (2001) Adult hepatitis B vaccination using a novel triple antigen recombination vaccine. Hepatology 34: 372-376
39. Nothdurft HD, Dietrich M, Zuckerman JN, Kobloch J, Kern P, Vollmar J, Sanger R (2002) A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 15: 1157-1162
40. Casey J (2000) Hepatitis D virus. In: American Association for the Study of Liver Diseases (ed) Update on viral hepatitis. Dallas, pp 83-87
41. Purcell RH (2000) Hepatitis E virus. In: American Association for the Study of Liver Diseases (ed) Update on viral hepatitis. Dallas, pp 61-67
42. Alter M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, type E. National Centers for Infectious Diseases-http://www.travellers-health.com
43. Teich N, Tannapfel A, Ammon A, Ruf BR, van der Poel WH, Mossner J, Liebert UG (2003) Sporadic acute hepatitis E in Germany: an underdiagnosed phenomenon? Z Gastroenterol 41: 419-423
44. Favorov MO, Kosoy MY, Tsarev SA, Childs JE, Margolis HS (2000) Prevalence of antibody to hepatitis E virus among rodents in the United States. J Infect Dis 181: 449-455
45. Aggarwal R, Krawczynski K (2000) Hepatitis E: an overview and recent advances in clinical and laboratory research. J Gastroenterol Hepatol 15: 9-20
46. Clayson ET, Myint KS, Snitbhan R et al. (1995) Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 172: 927-933
47. Jilg W (2004) Hepatitis-E-Virus. In: Adam D, Doerr HW, Link H, Lode H (Hrsg) Die Infektiologie. Springer, Berlin Heidelberg New York Tokio, S 884-885
48. Khuroo MS, Dar MY (1992) Hepatitis E: evidence for person-to-person transmission and inability of low dose immune serum globulin from an Indian source to prevent it. Indian J Gastroenterol 11: 113-116
49. After M, Bell B, Fiore A, Mast E, Moyer L (2003) Viral hepatitis, type C. National Centers for Infectious Diseases-http://www.travellers-health.com
50. Jaeckel E, Cornberg M, Wedemeyer H et al. (2001) Treatment of acute hepatitis C with interferon-α2b. N Engl J Med 345: 1452-1457
51. Robert-Koch-Institut (2001) Zu Übertragungswegen und Übertragungsfaktoren der Hepatitis A - Ergebnisse einer epidemiologischen Untersuchung in Hamburg. Epidemiol Bull 50: 383-384
52. Maier K, Gabriel P, Koscielniak E et al. (1988) Human gamma interferon production by cytotoxic T lymphocytes sensitized during hepatitis A virus infection. J Virol 62: 3756-3763
53. Ostapowicz G, Fontana RJ, Schiodt FV et al. (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137: 947-954
54. Werzberger A, Mensch B, Nalin DR, Kuter BJ (2002) Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years follow-up after the Monroe field trial of VAQTA. Vaccine 20: 1699-1701
55. Van Damme P, Banatvala J, Fay O et al. (2003) Hepatitis A booster vaccination: is there a need? Lancet 362: 1065-1071
56. Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S (2003) Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z Gastroenterol 41: 983-990
57. Tei S, Kitajima N, Takahashi K, Mishiro S (2003) Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362: 371-373